Compare BAK & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAK | MPLT |
|---|---|---|
| Founded | 1972 | 2018 |
| Country | Brazil | United States |
| Employees | N/A | 133 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2002 | N/A |
| Metric | BAK | MPLT |
|---|---|---|
| Price | $2.45 | $36.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $4.40 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 2.1M | 563.2K |
| Earning Date | 05-12-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.02 | N/A |
| Revenue Next Year | $7.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.25 | $12.24 |
| 52 Week High | $5.40 | $40.43 |
| Indicator | BAK | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 40.11 | 54.74 |
| Support Level | $2.32 | $26.20 |
| Resistance Level | $2.78 | $40.43 |
| Average True Range (ATR) | 0.14 | 2.75 |
| MACD | 0.05 | -0.46 |
| Stochastic Oscillator | 40.20 | 35.78 |
Braskem SA is engaged in the manufacture, sale, import and export of chemicals, petrochemicals and fuels, as well as the production, supply and sale of utilities such as steam, water, compressed air and industrial gases. It also provides industrial services and is engaged in the production, supply and sale of electric energy and gas for its own use and use by other companies. Its segments include Brazil, USA and Europe; and Mexico. The Brazil segments delivered the majority of the revenue from the production and sale of chemicals; the supply of electricity and other inputs produced in these complexes to second-generation producers located in the petrochemical complexes; and the production and sale of PE, including the production of green PE made from renewable resources, and of PP.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.